We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA to Ask Advisory Panel to Reconsider Ardelyx’s Kidney Drug
FDA to Ask Advisory Panel to Reconsider Ardelyx’s Kidney Drug
Ardelyx said the FDA will convene an advisory committee meeting to review the company’s Xphozah (tenapanor) as a treatment for the control of serum phosphorus in adults suffering from chronic kidney disease who are on dialysis.